Skip to main content

Table 1 Characteristics of eligible studies

From: Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review

StudyYearTypePopulationPlatinum-based regimenNonplatinum regimenOutcomes
GEICAM/2006–03 [19]2012Randomized phase 2 trialTNBCEC × 4 ➔ DCb ×  4 cyclesEC ×  4 ➔ D ×  4 cyclespCR:
EC-D 35%
EC-DCb 45%
(p = 0.606)
Ando [20]2014Randomized phase 2 trialTNBCCP q wk. x 12 ➔ CEF × 4 cyclesP q wk. × 12 ➔ CEF ×  4 cyclespCR:
CP-CEF 31.8%
P-CEF 17.6%
(p = 0.01)
WSG-ADAPT-TN [21]2017Randomized phase 2 trialTNBCNab-P/
Cb × 4
Nab-P/ Gem ×  4pCR
Nab-P-Cb 45.9%
Nab-P-Gem 28.7%
p = 0.002
BrighT
Ness [22]
2018Randomized phase 3 trialTNBCArm 1: PCb + Veliparib × 4 cycles
Arm 2: PCb + Veliparib placebo ×  4 cycles
Arm 3: Paclitaxel + Carboplatin placebo + Veliparib placebo ×  4 cyclespCR
Arm 1 53%
Arm 2 58%
Arm 3 31%
CALGB 40603 [11]2015Randomized phase 2 trialTNBCArm 3: P x 12w + Cb ×  4 ➔ ddAC ×  4
Arm 4: P × 12w + Cb ×  4 + Bev ×  9 ➔ ddAC ×  4
Arm 1: P x 12w ➔ ddAC ×  4
Arm 2: P ×  12w + Bev q2w x 9w ➔ ddAC ×  4
pCR
(+) Cb 60%
(−) Cb 46%
(+) Bev 59%
(−) Bev 48%
TNT Trial [23]2018Randomized phase 3 trialTNBCCbDpCR
Cb 6.7%
D 3.3%
Gepar
Sixto [4]
2014Randomized phase 2 trialTNBCCb + PDB x 18w or Cb + PDH x 18wPDB x 18w or PDH x 18wpCR
(+) Cb 43.7%
(−) Cb 36.9%
Zhang [24]2016Randomized phase 2 trialTNBCPCbEPpCR
PCb 38.6%
EP 14.0%
CBCSG006 [17]2015Randomized phase 3 trialMetastatic TNBCGemcitabine/ Cisplatin × 8 cyclesGemcitabine / Paclitaxel ×  8 cyclesOS
Gem/Cis ×  8 59%
Gem/P ×  8 58%
p = 0.611
Carey [16]2012Randomized phase 2 trialMetastatic TNBCCet/ CbCetPFS:
Cet + Cb 77%
Cb 97%
OS:
Cet + Cb 83%
Cb 83%
Fan [25]2012Randomized phase 2 trialMetastatic TNBCDP × 6 cyclesDX ×  6 cyclesPFS:
TP 25%
TX 10%
p < 0.001
OS
TP 28%
TX 10%
p = 0.02
  1. [pCR = pathological complete response; DFS = Disease free survival; CRR = Complete response rate; OS = Overall survival; RR = Response rate; E = Epirubin; C/Cb = Carboplatin; D = Docetaxel; CEF = Cyclophosphamide/Epirubicin/5-Fluorouracil; P = Paclitaxel; Cet = Cetuximab; DP = Docetaxel/Cisplatin DX = Docetaxel/Capecitabine; Nab-P = Nab-Paclitaxel; Gem = Gemcitabine; ddAC Doxorubicin/Cyclphosphamide; Bev = Bevacizumab; H = Trastuzumab]